Securities Code: 000952 Securities Abbreviation: Guangji Pharmaceutical Hubei Guangji Pharmaceutical Co., Ltd. Announcement No.: 2026-056
Announcement on the Draft (Revised) and Explanation of Revisions Regarding the Proposed Issuance of A Shares by Hubei Guangji Pharmaceutical Co., Ltd. to Specific Objects in 2026
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from any false records, misleading statements, or major omissions.
Hubei Guangji Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") has had the relevant matters concerning the proposed issuance of A shares to specific objects in 2026 reviewed and approved by the fifteenth (extraordinary) meeting of the eleventh Board of Directors.
The Company convened the nineteenth (extraordinary) meeting of the eleventh Board of Directors on July 20, 2026. Given that the Company has adjusted the issuance plan, it reviewed and approved the "Proposal on Adjusting the Company's 2026 Plan for Issuing A Shares to Specific Objects" and the "Proposal on the Draft (Revised) of the Company's 2026 Plan for Issuing A Shares to Specific Objects," among other proposals related to the Company's issuance of shares to specific objects. In accordance with the resolution of the nineteenth (extraordinary) meeting of the eleventh Board of Directors, the revisions to the draft issuance plan (revised) and related documents are as follows:
I. Revisions to the Company's "Draft (Revised) of the 2026 Plan for Issuing A Shares to Specific Objects"